NCT02273388 2023-10-03
BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
Clinical Trials
17 trialsNCT01772563 2023-09-01
Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT00969553 2019-07-26
Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers
Boehringer Ingelheim
Phase 1 Completed
NCT01957644 2019-02-08
Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML
Boehringer Ingelheim
Phase 1 Terminated
NCT01206816 2019-02-01
An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT00969761 2019-01-31
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
Boehringer Ingelheim
Phase 1 Completed
NCT01145885 2019-01-31
BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT01348347 2018-08-06
BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT01022853 2018-07-30
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT01662505 2018-07-30
Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)
Boehringer Ingelheim
Phase 1 Completed
NCT01971476 2018-07-30
Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known
Boehringer Ingelheim
Phase 1 Completed
NCT02201329 2018-07-30
Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Boehringer Ingelheim
Phase 1 Completed
NCT02905994 2018-05-04
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
Massachusetts General Hospital
Phase 1 Withdrawn
NCT02875002 2017-12-22
Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
Yale University
Phase 1 Withdrawn
NCT02527174 2017-04-05
VIAC
University of Alberta
Phase 1 Withdrawn
NCT02722135 2017-01-27
A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed
Boehringer Ingelheim
Phase 1 Withdrawn
NCT02861040 2016-12-15
Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Northwestern University
Phase 1 Withdrawn